Matthew Jenusaitis

Matthew M.
Jenusaitis currently serves as Independent Director at enVVeno Medical Corp.
since 2019.
He is Director at NeuroInterventional Therapeutics, Inc., a member of the Industry Advisory Board at MergerTech Capital Management LLC, and Chief Administrative Officer at Moores Cancer Center.
Former roles include President & Chief Executive Officer at Micro Therapeutics, Inc.; Chairman & Chief Executive Officer at Avantis Medical Systems, Inc. in 2011; President & Chief Executive Officer at OCTANe Foundation for Innovation and OCTANe from 2009 to 2015; Director at Pulsar Vascular, Inc. from 2008 to 2017; Director at Precision Wire Components LLC from 2009 to 2014; Director at Creagh Medical Ltd. from 2008 to 2015; President-Peripheral Interventions at Boston Scientific Corp.
from 2003 to 2005; President-Neurovascular Division & Senior VP at ev3, Inc. from 2006 to 2008; Principal at ConcepTx Medical, Inc.; and Chief of Staff at UC San Diego Health System.
Education includes graduate studies at Arizona State University, undergraduate studies at Cornell University, and an MBA from the University of California, Irvine.